Clinical Trial Update: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of lenvatinib and pembrolizumab in differentiated thyroid cancers has completed, with results posted in October 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Follicular Thyroid Carcinoma
• Hurthle Cell Carcinoma of the Thyroid
• Papillary Thyroid Carcinoma
• Papillary Thyroid Carcinoma Tall Cell Variant
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-10-24